Progyny (NASDAQ: PGNY) is one of 27 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its peers? We will compare Progyny to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, dividends, analyst recommendations and profitability.
Earnings and Valuation
This table compares Progyny and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Progyny | $344.86 million | $46.46 million | 340.17 |
| Progyny Competitors | $1.94 billion | $96.17 million | 40.54 |
Progyny’s peers have higher revenue and earnings than Progyny. Progyny is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Progyny has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Progyny’s peers have a beta of 7.02, meaning that their average share price is 602% more volatile than the S&P 500.
Institutional & Insider Ownership
81.5% of Progyny shares are held by institutional investors. Comparatively, 44.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 33.3% of Progyny shares are held by company insiders. Comparatively, 25.5% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings for Progyny and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Progyny | 0 | 1 | 5 | 0 | 2.83 |
| Progyny Competitors | 92 | 389 | 536 | 15 | 2.46 |
Progyny currently has a consensus price target of $43.40, indicating a potential downside of 29.12%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 15.53%. Given Progyny’s peers higher possible upside, analysts clearly believe Progyny has less favorable growth aspects than its peers.
Profitability
This table compares Progyny and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Progyny | 14.97% | 17.31% | 11.16% |
| Progyny Competitors | -39.15% | 16.05% | -9.95% |
Summary
Progyny beats its peers on 8 of the 13 factors compared.
Progyny Company Profile
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.